Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$14.1 million.

  • Beam Therapeutics' Net Cash Flow rose 7723.96% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.9 million, marking a year-over-year decrease of 3584.87%. This contributed to the annual value of -$154.5 million for FY2024, which is 17760.34% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Net Cash Flow is -$14.1 million, which was up 7723.96% from -$245.8 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Net Cash Flow high stood at $400.0 million for Q3 2021, and its period low was -$263.2 million during Q1 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$18.6 million (2023), whereas its average is $5.1 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 1544411.76% in 2021, then tumbled by 542276.37% in 2025.
  • Beam Therapeutics' Net Cash Flow (Quarter) stood at -$54.1 million in 2021, then skyrocketed by 240.9% to $76.3 million in 2022, then soared by 249.97% to $266.9 million in 2023, then crashed by 80.01% to $53.4 million in 2024, then tumbled by 126.52% to -$14.1 million in 2025.
  • Its Net Cash Flow stands at -$14.1 million for Q3 2025, versus -$245.8 million for Q2 2025 and $244.4 million for Q1 2025.